ABVC BioPharma, Inc (ABVC): Forvard P/S multiplikatori
ABVC BioPharma resurslarni optimallashtirish va botanika tibbiyotida qayta ishlangan qadoqlardan foydalanish orqali ESG tamoyillariga amal qiladi. Ushbu kelajakdagi sotuvlar nisbatidagi narx grafigi bozor kutimlari tendentsiyalarini vizuallashtiradi, bunda 43.70 ko'rsatkichi joriy kapitalizatsiya holatini belgilaydi. Biznes muvaffaqiyati ADHD va depressiyani davolash vositalarining royalti orqali litsenziyalanishiga bog'liq. Kompaniya hozirda o'zining innovatsion ishlanmalari uchun II bosqich sinovlari natijalarini tayyorlamoqda.
ABVC BioPharma, Inc (ABVC) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- birja kapitallashuvi ma'lumotlari:
- emitentning balans qiymati statistikasi:
- biznesning qarz tarkibi va likvidligi tafsilotlari:
Umumiy qarzning xususiy kapitalga nisbati ABVC BioPharma|ABVC - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning kapitalga nisbati ABVC BioPharma|ABVC - Kompaniya qarzlari|Balans kapitallashuviga qarzlar ABVC BioPharma, Inc|ABVC - Uzoq muddatli qarz hajmi|Kompaniyaning qisqa muddatli qarzi ABVC BioPharma|Tezkor likvidlik abvcpharma.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
ABVC - Soliqdan keyingi foyda|Prognoz qilingan kelajakdagi foyda ABVC BioPharma|ABVC - Kompaniya qiymatining sof foydaga nisbati|Forvard P/E multiplikatori ABVC BioPharma Inc|ABVC - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati ABVC BioPharma, Inc|ABVC - Foizlar, soliqlar va amortizatsiya chegirilmasdan oldingi daromad|So'nggi o'n ikki oy davomida bir aksiya uchun foyda ABVC BioPharma|ABVC - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi abvcpharma.com|ABVC - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi ABVC BioPharma
- sotishdan tushum va biznes daromadlari ko'rsatkichlari:
Kompaniyaning jamlanma tahliliyoti:ABVC BioPharma, Inc. ABVC
Oldingi P/S ko'rsatkichi bozor kapitalizatsiyasining kutilayotgan daromadga nisbatini aks ettiradi va bu potentsial savdo o'sishi uchun to'langan premiumni baholash imkonini beradi. Oldingi P/S metrikasini tahlil qilish orqali investor daromadlarining beqaror litsenziyalash shartnomalariga bog'liqligi va kompaniyaning ishchi kapital likvidligining cheklanganligini hisobga olgan holda ABVC BioPharma uchun haddan tashqari yuqori baholanganlik xavfini aniqlashi mumkin.
Raqobatdosh kompaniyalar tahlili
Forvard P/S multiplikatori HLN (Haleon)|Forvard P/S multiplikatori Kenvue Inc KVUE|Verona Pharma Corp - Forvard P/S multiplikatori|MENS: Narxning prognoz qilingan daromadga nisbati|LGND (Ligand Pharmaceuticals) - Forvard narx/daromad multiplikatori|AMRX (amneal.com) - Narxning prognoz qilingan daromadga nisbati|PRGO (Perrigo) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Alvotech S.A. (ALVO)|Forvard narx/daromad multiplikatori LQDA (Liquidia Technologies)|GLPG (Galapagos Corp) - Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori ANIP (ANI Pharmaceuticals)|mannkindcorp.com - Narxning prognoz qilingan daromadga nisbati|Amphastar Pharmaceuticals, Inc. - Forvard P/S multiplikatori|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Pacira Pharmaceuticals PCRX|ARS Pharma (SPRY) - Narxning prognoz qilingan daromadga nisbati|Bozor kapitallashuvining kelajakdagi daromadga nisbati Theravance Corp (TBPH)|Narxning prognoz qilingan daromadga nisbati Aquestive Therapeutics|scPharma - Kelajakdagi narxning daromadga nisbati|Forvard P/S multiplikatori TECX|TNXP (Tonix Pharma) - Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori SXTC (China SXT Pharmaceuticals, Inc.)|Forvard P/S multiplikatori Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Narxning prognoz qilingan daromadga nisbati|Sotuvga nisbatan forvard narx EXOZ (invizyne.com)|oramed.com (ORMP) - Narxning prognoz qilingan daromadga nisbati|Forvard narx/daromad multiplikatori Entera Bio|HYFT (MindWalk) - Forvard P/S multiplikatori|Forvard P/S multiplikatori Cumberland Corp|Forvard P/S multiplikatori QNTM|Forvard P/S multiplikatori fibrogen.com (FGEN)|Forvard P/S multiplikatori TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings - Narxning prognoz qilingan daromadga nisbati|SNYR: Forvard narx/daromad multiplikatori|RLYB: Narxning prognoz qilingan daromadga nisbati|LEXX: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori pulmatrix.com|Narxning prognoz qilingan daromadga nisbati Pheton Holdings Limited|Aptorum - Kelajakdagi narxning daromadga nisbati|Forvard P/S multiplikatori LYRA|IBO (Impact BioMedical, Inc.) - Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori TNFA (TNF Pharmaceuticals, Inc.)|Forvard P/S multiplikatori cbdMD Inc. YCBD|PRFX - Narxning prognoz qilingan daromadga nisbati|Sotuvga nisbatan forvard narx CYTO (Altamira Therapeutics)|Lipella (LIPO) - Narxning prognoz qilingan daromadga nisbati|Forvard narx/daromad multiplikatori OptiNose Corp|PIRS (Pieris Pharmaceuticals) - Forvard P/S multiplikatori|Forvard P/S multiplikatori procapsgroup.com|Forvard narx/daromad multiplikatori PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding Group) - Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati ACELYRIN, Inc. SLRN|TFF Pharmaceuticals, Inc (TFFP) - Bozor kapitallashuvining kelajakdagi daromadga nisbati
